Clinical Trial Update: DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD. [Phase 1]

View source ↗

Summary

Phase 1 trial update for ASC41, including a drug-drug interaction study in healthy volunteers and pharmacokinetics, safety, and tolerability in subjects with no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• ASC41

Snippet

Sponsor: Gannex Pharma Co., Ltd. | Conditions: Healthy, NAFLD | Phase 1 | Status: COMPLETED